TY  - CHAP
M1  - Book, Section
TI  - Chapter 22. Treatment of Systemic Lupus Erythematosus
A1  - Dall'Era, Maria
A1  - Wofsy, David
A2  - Imboden, John B.
A2  - Hellmann, David B.
A2  - Stone, John H.
PY  - 2013
T2  - CURRENT Diagnosis & Treatment: Rheumatology, 3e
AB  - Systemic  lupus  erythematosus  (SLE)  is  a  heterogeneous,  multisystem  disease.  SLE  manifests  in  a  unique  way  in  each  patient,  and  treatment  should  be  tailored  to  the  type  and  severity  of  organ  system  involvement  (Table  22–1).  Unfortunately,  this  is  more  easily  said  than  done,  because  there  are  few  large  studies  to  guide  decision-making.  The  lack  of  large  scale,  randomized  controlled  trials  has  resulted  in  therapeutic  strategies  that  are  largely  empiric.  Despite  these  limitations,  well-accepted  community  standards  exist  and  are  helpful  in  guiding  treatment.  In  the  end,  the  patient  and  his  or  her  physician  must  weigh  the  potential  risks  and  benefits  of  a  particular  therapy  and  agree  upon  a  course  of  action.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=57272395
ER  -